Cefotaxime (Mayne Pharma) is a medicine containing the active ingredient(s) cefotaxime. On this page you will find out more about Cefotaxime (Mayne Pharma), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: cefotaxime
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Cefotaxime (Mayne Pharma) 1 g powder for injection, 10 vials
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
INDICATIONS: Cefotaxime is indicated for the treatment of the following types of injection when caused by susceptible micro-organisms: Infections of the respiratory tract (upper and lower). Infections of the urinary tract. Septicaemia - concomitant therapy with an aminoglycoside may be instituted prior to isolation of the causative organism. Intra-abdominal infection. Gonorrhoea (including gonorrhoea caused by beta lactamase producing strains of N. gonorrhoeae). Ear, nose and throat infections. Skin and skin structure infections. Bone and joint infections. Meningitis - cefotaxime should be combined with an appropriate alternative antibiotic (ampicillin, chloramphenicol or pencillin G) for initial therapy in children, (excluding neonates) pending the availability of culture and sensitivity results. In adults, the empirical use of cefotaxime should be restricted to patients suspected of having meningitis caused by Gram negative enteric bacilli. Cefotaxime may be used for the prevention of post-operative infection in obstetrical surgery, vaginal and abdominal hysterectomy and biliary surgery. In serious cases, cefotaxime may be used, if considered appropriate,before the results of sensitivity tests become available. The emergency of resistance to cefotaxime may complicate treatment.
Table of characteristics
|Visual appearance||Clear glass vial containing a white to pale yellow crystalline powder.|
|Dosage Form||Injection, powder for|
|Route of administration||Intravenous|
1 vial: Prescription Only Medicine, or Prescription Animal Remedy
10 vials: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||Protect from Light|
|Life time||3 Years|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.